Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | POLG | P54098 | 2/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036658 | 1.00 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL598444 | 1.00 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL27820622 | 1.00 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL25082481 | 0.91 | LMNA (0.56) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL846006 | 0.88 | LMNA (0.53) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL13036646 | 0.88 | LMNA (0.53) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL25386540 | 0.88 | LMNA (0.53) | LMNAPDE3ACACNA1FALBMAPT | |
| Doxecitine SCHEMBL23178 | 0.87 | DNMT1 (0.66) | LMNAPDE3ACACNA1FALBMAPT | |
| Doxecitine SCHEMBL23346798 | 0.87 | DNMT1 (0.66) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL21423133 | 0.87 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| EP-2509949-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | University Of Georgia Research Foundation, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071849-A2 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-7829548-B2 | Compounds useful in the treatment of HIV | MEDIVIR AB (SE) | 2010-11-09 | — | — | US | claimed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1835916-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF HIV | MEDIVIR AB (SE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20050238738-A1 | Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed | TSI GROUP LIMITED (HK) | 2005-10-27 | — | — | US | claimed |
| US-20050226948-A1 | Methods for enhancing the transport of glucose into muscle | TECHNICAL SOURCING INTERNATIONAL, INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005084323-A2 | COMPOSITIONS OF BIO-ACTIVE COMPOUNDS FROM FENUGREEK SEED AND METHODS FOR PRODUCING SAME | TECHNICAL SOURCING INTERNATIONAL, INC. (US) | 2005-09-15 | — | — | WO | claimed |
| EP-3993645-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE TO PRODUCE INTRACELLULAR NAD+ | Société des Produits Nestlé S.A. (CH) | 2022-05-11 | — | — | EP | disclosed |
| EP-3993770-A1 | COMPOSITIONS AND METHODS USING TRIGONELLINE TO PRODUCE INTRACELLULAR NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) FOR TREATING OR PREVENTING PHYSIOLOGICAL DISORDERS OR STATES | Société des Produits Nestlé S.A. (CH) | 2022-05-11 | — | — | EP | disclosed |
| EP-1284741-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | Pharmasset, Ltd. (BB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050226948-A1 | Methods for enhancing the transport of glucose into muscle | GYS1, SLC2A3, MUSK | LMNA 3659/4885PDE3A 3376/4885CACNA1F 2903/4885 |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | LMNA 1253/4885PDE3A 2437/4885CACNA1F 4844/4885 |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | LMNA 3285/4885PDE3A 2252/4885CACNA1F 4818/4885 |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | LMNA 3895/4885PDE3A 1789/4885CACNA1F 4632/4885 |
| US-20050238738-A1 | Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed | SHBG, SIK3, HGFAC | LMNA 3909/4885PDE3A 3322/4885CACNA1F 3391/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | LMNA 1899/4885PDE3A 779/4885CACNA1F 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.